MedPath

Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF

Phase 3
Completed
Conditions
Short Bowel Syndrome
Interventions
Registration Number
NCT04627025
Lead Sponsor
VectivBio AG
Brief Summary

The primary objective of the trial is the confirmation of the efficacy of apraglutide to evaluate the efficacy of weekly subcutaneous apraglutide in reducing parenteral support dependency.

Detailed Description

This is an international, multicenter, double-blind, randomized, placebo-controlled, trial to evaluate the efficacy and safety of weekly SC injections of apraglutide in adult subjects with SBS-IF. The active pharmaceutical ingredient is apraglutide, a GLP-2 analogue.

The trial consists of a screening phase, a treatment phase of 48 weeks, and a safety follow-up phase. Trial participants will receive, after successful screening, once weekly apraglutide.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
164
Inclusion Criteria

Not provided

Exclusion Criteria
  1. Pregnancy or lactation.
  2. Major abdominal surgery in the last 6 months prior to screening.
  3. History of cancer (including colon carcinoma) or clinically significant lymphoproliferative disease within ≤5 years, except for adequately treated basal cell skin cancer.
  4. Evidence of active inflammatory GI conditions in the previous 6 months.
  5. Evidence of decompensated heart failure.
  6. Evidence of severe renal or hepatic impairment.
  7. Any previous use of growth factors such as growth hormone (GH), native GLP-2, GLP-1, or GLP-2 or GLP-1 analogues should be discussed with the Investigator.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Apraglutide SC injections, once weeklyapraglutidePeptide analogue of GLP-2
PlaceboapraglutidePlacebo for apraglutide, SC injection once weekly
Primary Outcome Measures
NameTimeMethod
Relative change from baseline in actual weekly PS volume at Week 24.At week 24 of treatment
Secondary Outcome Measures
NameTimeMethod
Apparent volume of distribution (Vz/F) of apraglutide through population PK data analysisWeeks 0 / 24 of treatment
Subjects who achieve a reduction of at least 1 day per week of PS at Weeks 24 / 48 (CIC only).Weeks 24 and 48 of treatment
At least 40% reduction of PS volume at Weeks 20 and 24 (Stoma only)Weeks 20 / 24 of treatment
Trough plasma concentrations (Ctrough) at every other visit during the prolonged dosing period (CIC only)Weeks 24 / 48 of treatment
Relative change from baseline in actual weekly PS volume at Weeks 12 / 24 / 48 (CIC only).Weeks 12 / 24 / 48 of treatment
Subjects reaching enteral autonomy at Weeks 24 / 48 (CIC only).Weeks 24 / 48 of treatment
At least 20% reduction of PS volume from baseline at Weeks 20 / 24.Weeks 20 / 24 of treatment
Calorie reduction in the PN at Weeks 24.Weeks 24 of treatment
Change from baseline on the Pittsburgh Sleep Quality Inventory (PSQI) at Weeks 24 / 48 (CIC only)Weeks 24 / 48 of treatment
Change from baseline on the Patient Global Impression of Change (PGIC) at Weeks 24 / 48 (CIC only)Weeks 24 / 48 of treatment.
Change from baseline on the Patient Global Impression of Treatment Satisfaction (PGI-TS) at week 24 and 48 (CIC only).Weeks 24 / 48 of treatment
Change from baseline on the Patient Global Impression of Satisfaction with Parenteral Support (PGI-SPS) at Week 24 and 48 (CIC only).Weeks 24 / 48 of treatment
Change from baseline on the Patient Global Impression of Parenteral Support Impact (PGI-PSI) at Week 24 and 48 (CIC only).Weeks 24 / 48 of treatment
Absorption rate constant (ka) of apraglutide through population PK data analysisWeeks 0 / 24 of treatment
Apparent clearance (CL/F) of apraglutide through population PK data analysisWeeks 0 / 24 of treatment

Trial Locations

Locations (68)

University of Szeged

🇭🇺

Szeged, Hungary

Duke University Hospital

🇺🇸

Durham, North Carolina, United States

Rigshospitalet - University Hospital Copenhagen

🇩🇰

Copenhagen, Denmark

Ronald Reagan UCLA Medical Center

🇺🇸

Los Angeles, California, United States

Henry Ford Medical Center - Columbus

🇺🇸

Novi, Michigan, United States

Mayo Clinic

🇺🇸

Rochester, Minnesota, United States

Northwestern University

🇺🇸

Chicago, Illinois, United States

Mount Sinai Medical Center

🇺🇸

New York, New York, United States

University of Nebraska Medical Center

🇺🇸

Omaha, Nebraska, United States

Cleveland Clinic Foundation

🇺🇸

Cleveland, Ohio, United States

Cincinnati Children's Hospital Medical Center

🇺🇸

Cincinnati, Ohio, United States

Vanderbilt University Medical Center, Center for Human Nutrition

🇺🇸

Nashville, Tennessee, United States

Hospital of the University of Pennsylvania

🇺🇸

Philadelphia, Pennsylvania, United States

University of Washington Medical Center

🇺🇸

Seattle, Washington, United States

University Hospital Foundation Favaloro

🇦🇷

Buenos Aires, Argentina

University Hospital Brno

🇨🇿

Brno, Czechia

University Hospital Brussels

🇧🇪

Brussels, Belgium

University Hospital Hradec Kralove

🇨🇿

Hradec Králové, Czechia

Universitair Ziekenhuis Leuven - Gasthuisberg

🇧🇪

Leuven, Vlaams Brabant, Belgium

University Hospital Plzen

🇨🇿

Pilsen, Czechia

Hospital Novy Jicin

🇨🇿

Nový Jičín, Czechia

University Hospital Kralovske Vinohrady, 2nd Internal Clinic

🇨🇿

Prague, Czechia

General University Hospital in Prague

🇨🇿

Prague, Czechia

Hôpital Beaujon

🇫🇷

Clichy, France

CHU Hôtel Dieu

🇫🇷

Nantes, France

Hôpital ARCHET II

🇫🇷

Nice, France

University Hospital Heidelberg

🇩🇪

Heidelberg, Germany

Hôpital Haut-Lévèque

🇫🇷

Pessac, France

Hospices Civils de Lyon

🇫🇷

Pierre Benite, France

Brabois Adults Hospital

🇫🇷

Vandœuvre-lès-Nancy, France

Asklepios Klinik St. Georg

🇩🇪

Hamburg, Germany

Charité - Universitätsmedizin Berlin

🇩🇪

Berlin, Germany

University Hospital Bonn

🇩🇪

Bonn, Germany

University Hospital Muenster

🇩🇪

Münster, Germany

Medical Centre, Hungarian Defence Forces

🇭🇺

Budapest, Hungary

University Polyclinic Foundation "Agostino Gemelli" - IRCCS

🇮🇹

Rome, Italy

Rambam Health Care Campus

🇮🇱

Haifa, Israel

Rabin Medical Center

🇮🇱

Petah-Tikva, Israel

Semmelweis University

🇭🇺

Budapest, Hungary

St. Imre University Teaching Hospital Budapest

🇭🇺

Budapest, Hungary

Polyclinic S. Orsola-Malpighi

🇮🇹

Bologna, Italy

Sheba Medical Center

🇮🇱

Tel HaShomer, Israel

Citta della salute e della Scienza di Torino Hospital

🇮🇹

Torino, Italy

Yokohama Municipal Citizen's Hospital

🇯🇵

Kanagawa, Japan

Yokohama City University Medical Center

🇯🇵

Kanagawa, Japan

National University Corportation Tohoku University Tohoku University Hospital

🇯🇵

Miyagi, Japan

JCHO Tokyo Yamate Medical Center

🇯🇵

Tokyo, Japan

Osaka University Hospital

🇯🇵

Osaka, Japan

The Catholic University of Korea, Seoul St. Mary's Hospital

🇰🇷

Seoul, Korea, Republic of

Asan Medical Center

🇰🇷

Soeul, Korea, Republic of

Alesund Hospital

🇳🇴

Ålesund, Norway

Stadmedica, Non-Public Healthcare Facility

🇵🇱

Bydgoszcz, Poland

Samsung Medical Center

🇰🇷

Soeul, Korea, Republic of

COPERNICUS Limited Liability Company

🇵🇱

Gdansk, Poland

M. Pirogow Provincial Specialized Hospital

🇵🇱

Łódź, Poland

Gastromed Poland Sp. z o.o.

🇵🇱

Lublin, Poland

Stanley Dudrick Multispecialty Hospital

🇵🇱

Skawina, Poland

University General Hospital Gregorio Maranon

🇪🇸

Madrid, Spain

University Hospital 12 de Octubre

🇪🇸

Madrid, Spain

University Hospital Virgen del Rocio

🇪🇸

Sevilla, Spain

University Hospitals Birmingham NHS Foundation Trust

🇬🇧

Birmingham, United Kingdom

Sahlgrenska University Hospital

🇸🇪

Göteborg, Sweden

Far Eastern Memorial Hospital

🇨🇳

New Taipei City, Taiwan

St Mark's Hospital

🇬🇧

Harrow, United Kingdom

Royal London Hospital

🇬🇧

London, United Kingdom

University College Hospital

🇬🇧

London, United Kingdom

Salford Royal Hospital

🇬🇧

Salford, United Kingdom

Gastroenterology Group of Naples

🇺🇸

Naples, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath